StreetInsider.com News Articles

Vaxcyte names new CMO, CLO and narrows VAX-31 data timeline

Thu, 03 Sep 2026 16:05:14 -0400

Vaxcyte, Inc. (Nasdaq: PCVX) announced the appointments of Luis Jodar, Ph.D. as Chief Medical Officer and David McAvoy, J.D. as Chief Legal Officer, according to a press release. The company also narrowed its guidance for topline data from its VAX-31 adult Phase 3 OPUS-1 trial, now expected by the end of October 2026, compared to the previously stated fourth-quarter 2026 timeframe.

Dr. Jodar spent 17 years at Pfizer Inc., most recently as Senior Vice President and Chief Medical Officer for Vaccines and Infectious Diseases, where he held senior roles in clinical development and regulatory strategy for products including Prevnar 13 and

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

Thu, 03 Sep 2026 16:05:00 -0400

Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjugate Vaccines Prevnar 13 and Prevnar 20, Joins Vaxcyte as Chief Medical Officer

David McAvoy, J.D., Former Teva Chief Legal Officer, Joins Vaxcyte as Chief Legal Officer

Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Pivotal Trial Expected by End of October 2026

SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

Thu, 03 Sep 2026 16:05:00 -0400

David McAvoy, J.D., Former Teva Chief Legal Officer, Joins Vaxcyte as Chief Legal Officer

Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Pivotal Trial Expected by End of October 2026

SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced

Vaxcyte to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 16:05:00 -0400

SAN CARLOS, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences:

Wells Fargo 21^st Annual Healthcare Conference, September 8-10, 2026: Fireside chat will take place on Tuesday, September 8 at 3:00 p.m. ET / 12:00 p.m. PT.
Cantor Global Healthcare Conference, September 9-11, 2026: Fireside chat will take place on Wednesday, September 9 at 2:45 p.m. ET / 11:45 a.m. PT.

A live webcast of the fireside

Vaxcyte to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 16:05:00 -0400

Wells Fargo 21^st Annual Healthcare Conference, September 8-10, 2026: Fireside chat will take place on Tuesday, September 8 at 3:00 p.m. ET / 12:00 p.m. PT.
Cantor Global Healthcare Conference, September 9-11, 2026: Fireside chat will take place on Wednesday, September 9 at 2:45 p.m. ET / 11:45 a.m. PT.

A live webcast of the fireside

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: Janus Henderson Group Ltd.

Tue, 11 Aug 2026 14:23:00 -0400

si-local-file:///var/storage/secattach/20260811/26904863.html

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: Janus Henderson Group Ltd.

Tue, 11 Aug 2026 14:23:00 -0400

si-local-file:///var/storage/secattach/20260811/26904863.html

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: Janus Henderson Group Ltd.

Fri, 07 Aug 2026 12:52:00 -0400

si-local-file:///var/storage/secattach/20260807/26889941.html

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: Janus Henderson Group Ltd.

Fri, 07 Aug 2026 12:52:00 -0400

si-local-file:///var/storage/secattach/20260807/26889941.html

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: FMR LLC

Thu, 06 Aug 2026 10:44:00 -0400

si-local-file:///var/storage/secattach/20260806/26881424.html

Form SCHEDULE 13G/A Vaxcyte, Inc. Filed by: FMR LLC

Thu, 06 Aug 2026 10:44:00 -0400

si-local-file:///var/storage/secattach/20260806/26881424.html

Form 4 Vaxcyte, Inc. For: Aug 05 Filed by: Dhaliwal Harpreet S.

Wed, 05 Aug 2026 19:01:00 -0400

si-local-file:///var/storage/secattach/20260805/26876459.html

Form 4 Vaxcyte, Inc. For: Aug 05 Filed by: Dhaliwal Harpreet S.

Wed, 05 Aug 2026 19:01:00 -0400

si-local-file:///var/storage/secattach/20260805/26876459.html

Vaxcyte, Inc. (PCVX) Tops Q2 EPS by 7c

Wed, 05 Aug 2026 18:23:44 -0400

Vaxcyte, Inc. (NASDAQ: PCVX) reported Q2 EPS of ($1.97), $0.07 better than the analyst estimate of ($2.04).

For earnings history and earnings-related data on Vaxcyte, Inc. (PCVX) click here.

Form 4 Vaxcyte, Inc. For: Aug 03 Filed by: Wassil Jim

Wed, 05 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260805/26875577.html

Form 4 Vaxcyte, Inc. For: Aug 03 Filed by: Wassil Jim

Wed, 05 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260805/26875577.html

Form 4 Vaxcyte, Inc. For: Aug 03 Filed by: GUGGENHIME ANDREW

Wed, 05 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260805/26875566.html

Form 4 Vaxcyte, Inc. For: Aug 03 Filed by: GUGGENHIME ANDREW

Wed, 05 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260805/26875566.html

Form 10-Q Vaxcyte, Inc. For: Jun 30

Wed, 05 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260805/26874486.html

Form 10-Q Vaxcyte, Inc. For: Jun 30

Wed, 05 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260805/26874486.html

Form 8-K Vaxcyte, Inc. For: Aug 05

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874189.html

Form 8-K Vaxcyte, Inc. For: Aug 05

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874189.html

Form 144 Vaxcyte, Inc. Filed by: Dhaliwal Harpreet S.

Wed, 05 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260805/26874042.html

Form 144 Vaxcyte, Inc. Filed by: Dhaliwal Harpreet S.

Wed, 05 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260805/26874042.html

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Wed, 05 Aug 2026 16:05:00 -0400

Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027

Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose of VAX-31 Infant Phase 2 Dose-Finding Study Expected Either Sequentially or Together by End of First Half of 2027

Company Initiated Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults; Topline Data Expected in Second Half of 2027

Approximately